Literature DB >> 2025243

Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9.

M E Veronese1, P I Mackenzie, C J Doecke, M E McManus, J O Miners, D J Birkett.   

Abstract

A human cytochrome P4502C9 cDNA clone has been isolated from a human liver bacteriophage Lambda gt11 library using oligonucleotide probes. Expression of the 1762 base pair cDNA in COS cells demonstrated that the encoded enzyme has a molecular mass of 55 kDa as determined by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. The expressed enzyme catalysed the methylhydroxylation of tolbutamide with an apparent Km of 131.7 microM, similar to that observed in human liver microsomes. P4502C9 also catalysed the 4-hydroylation of phenytoin, and inhibition experiments demonstrated that phenytoin was a competitive inhibitor of tolbutamide hydroxylation with an apparent Ki of 19.1 microM. Sulphaphenazole was a potent inhibitor of the expressed enzyme with respect to both tolbutamide and phenytoin hydroxylations. These data demonstrate that a single isozyme can catalyse the hydroxylations of both tolbutamide and phenytoin, and suggest that both reactions are mediated by the same isozyme(s) of cytochrome P450 in human liver.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2025243     DOI: 10.1016/0006-291x(91)91680-b

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  33 in total

1.  Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity.

Authors:  K A Bachmann; T J Sullivan; L Jauregui; J H Reese; K Miller; L Levine
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

2.  The use of urine to clarify the genotype of a patient with toxic phenytoin concentrations who had undergone peripheral blood stem cell transplantation.

Authors:  Noritaka Ariyoshi; Katsuhiro Sho-no; Miki Nishimura; Michihiro Ito; Hiroyoshi Nakamura; Takayoshi Asai; Yasushi Saitoh; Takashi Ishizaki; Mitsukazu Kitada
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 3.  Rate and extent of drug accumulation after multiple dosing revisited.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

Review 4.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 5.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam.

Authors:  P Bonnabry; T Leemann; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 7.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

Review 8.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

9.  The effect of tenidap sodium on the disposition and plasma protein binding of phenytoin in healthy male volunteers.

Authors:  R A Blum; J J Schentag; M J Gardner; K D Wilner
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

10.  Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.

Authors:  Julia Kirchheiner; Ingolf Meineke; Nadine Steinbach; Christian Meisel; Ivar Roots; Jürgen Brockmöller
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.